Excitement and Anticipation Surround the 2023 AACC Annual Scientific Meeting
|
By Jen A. Miller (AACC) Posted on 07 Jul 2023 |

Illustration
What’s it like to spend more than a year planning a scientific meeting for 20,000 people, and then be on the precipice of all that work being realized? “Exciting,” said Amy Saenger, PhD, DABCC, FAACC, chair of AACC’s 12-member volunteer Annual Meeting Organizing Committee (AMOC). She expressed her anticipation as the meeting is set to return to pre-COVID-19 attendance numbers for the first time in years.
CLN spoke to her about the process of planning this year’s meeting and what attendees should expect.
WHAT ARE YOU LOOKING FORWARD TO THE MOST ABOUT THIS YEAR’S MEETING?
I’m mostly looking forward to having it be more like a normal meeting again, with almost everything in person. We expect attendance numbers to be back to or exceeding where they were prepandemic. I think we’re all looking forward to just getting back to ‘normal.’”
At the same time, we’re also offering virtual options for some of our sessions. We’ve improved the delivery of virtual content to ensure attendees can access the information they need. While our aim is to have people attend in person, we acknowledge that it may not work for everyone, so we want to ensure they have the opportunity to participate.
HOW HAVE CHANGES IN LAB MEDICINE AFFECTED THE CONTENT OF THE MEETING?
We've taken a targeted approach and conducted extensive outreach for our sessions, which has been incredibly successful. The content now showcases more innovative approaches to lab medicine, expanding beyond the traditional laboratory setting. For example, during the pandemic, clinical laboratories adapted their testing methods to serve homeless shelters, correctional facilities, and long-term care facilities. We’ll have sessions exploring these novel approaches and a broader focus on population health.
Clinical laboratorians have a lot of exciting things to share. We’re going to see a lot of cutting-edge science that’s coming out of lab medicine and clinical chemistry.
WHAT ELSE CAN ATTENDEES EXPECT THIS YEAR?
For this meeting, we’ve made a lot of changes to the format of the program that the AMOC is enthusiastic about. For example, we opened the poster sessions to all attendees, whether they’re expo only attendees or full conference attendees. We did that because we’re trying to increase the visibility of the posters and abstract presentations for everybody. It’s a good and significant change.
We also changed the topics of the posters and the abstracts to better align with our AACC divisions, and we are hoping to increase attendance there. If divisions decide to do poster walks again, they can more easily do so. This is a return to how we did things a few years ago, and we realized this worked well, so we made the change.
We also were able to work with the AACC’s journal Clinical Chemistry so that all our abstracts are indexed in the journal. I believe this also will boost visibility for all our authors, who put a lot of time and effort into doing these studies and presenting them.
Overall, attendees can expect to see a lot of excellent cutting-edge science and research in the field of laboratory medicine, and they should expect to have a lot of fruitful discussions and collaborations with their colleagues and other professionals in the field.
CLN spoke to her about the process of planning this year’s meeting and what attendees should expect.
WHAT ARE YOU LOOKING FORWARD TO THE MOST ABOUT THIS YEAR’S MEETING?
I’m mostly looking forward to having it be more like a normal meeting again, with almost everything in person. We expect attendance numbers to be back to or exceeding where they were prepandemic. I think we’re all looking forward to just getting back to ‘normal.’”
At the same time, we’re also offering virtual options for some of our sessions. We’ve improved the delivery of virtual content to ensure attendees can access the information they need. While our aim is to have people attend in person, we acknowledge that it may not work for everyone, so we want to ensure they have the opportunity to participate.
HOW HAVE CHANGES IN LAB MEDICINE AFFECTED THE CONTENT OF THE MEETING?
We've taken a targeted approach and conducted extensive outreach for our sessions, which has been incredibly successful. The content now showcases more innovative approaches to lab medicine, expanding beyond the traditional laboratory setting. For example, during the pandemic, clinical laboratories adapted their testing methods to serve homeless shelters, correctional facilities, and long-term care facilities. We’ll have sessions exploring these novel approaches and a broader focus on population health.
Clinical laboratorians have a lot of exciting things to share. We’re going to see a lot of cutting-edge science that’s coming out of lab medicine and clinical chemistry.
WHAT ELSE CAN ATTENDEES EXPECT THIS YEAR?
For this meeting, we’ve made a lot of changes to the format of the program that the AMOC is enthusiastic about. For example, we opened the poster sessions to all attendees, whether they’re expo only attendees or full conference attendees. We did that because we’re trying to increase the visibility of the posters and abstract presentations for everybody. It’s a good and significant change.
We also changed the topics of the posters and the abstracts to better align with our AACC divisions, and we are hoping to increase attendance there. If divisions decide to do poster walks again, they can more easily do so. This is a return to how we did things a few years ago, and we realized this worked well, so we made the change.
We also were able to work with the AACC’s journal Clinical Chemistry so that all our abstracts are indexed in the journal. I believe this also will boost visibility for all our authors, who put a lot of time and effort into doing these studies and presenting them.
Overall, attendees can expect to see a lot of excellent cutting-edge science and research in the field of laboratory medicine, and they should expect to have a lot of fruitful discussions and collaborations with their colleagues and other professionals in the field.
Latest AACC 2023 News
- First-of-Its-Kind Single-Cell Clinical Microbiology Platform Wins 2023 Disruptive Technology Award
- Ground-Breaking Phage-Based Diagnostic Kit for Laboratory Tuberculosis Testing Presented at AACC 2023
- Laboratory Experts Show How They Are Leading the Way on Global Trends
- Unique Competition Focuses on Using Data Science to Forecast Preanalytical Errors
- Best Approach to Infectious Disease Serology Testing for Laboratorians and Clinicians Discussed at AACC 2023
- Breaking Research Throws Light on COVID, Flu, and RSV Co-Infections
- New Research Shows Self-Collected Tests Perform Similarly to Provider-Collected Tests for Detecting STIs
- AI Predicts Multiple Sclerosis Risk, Flags Potentially Contaminated Lab Results
- Scientific Session Explores Role of Technology in New Era of Specimen Transport
- Prevencio Presents AI-Driven Platform for Medical Diagnostic Test Development
- Scientific Session Explores Future Role of AI and ML in Clinical Laboratory
- SARSTEDT Demonstrates Pre-Analytic Innovations for Improving Specimen Quality, Reducing TAT and Automating Labs
- World's First Large Sample Volume, Open-Assay, Super-fast, Ultra-Sensitive, and Sample-To-Answer PCR Instrument
- Vital Biosciences Unveils Revolutionary POC Lab Testing Platform
- World's Smallest POC Device for Complete Blood Count in 30 Minutes Unveiled
- General Biologicals Unveils CTC Cancer Detection Products and Automated Molecular System
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more





 assay.jpg)



